# US 2012/0252904 A1 · Mitf as a marker for predisposition to cancer

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2012/0252904 A1
- Document ID: US20120252904A1
- Status: Published application
- Kind: A1
- Application number: 13/515,984
- Filed: 2010-12-21
- Published: 2012-10-04
- Earliest claimed: 2009-12-21
- Assignees: Institut Gustave Roussy; Universite Sophia Nice Antipolis; Inserm (Institut National De La Sante Et De La Recherche Medicale)
- Inventors: Robert Ballotti; Corine Bertolotto; Brigitte Bressac De Paillerets; Mahaut De Lichy; Fabienne Lesueur
- Web page: https://patentgrep.com/patent/US20120252904A1

## CPC

- C12Q 1/6886: for cancer (immunoassay for cancer G01N33/575)
- A61P 35/00: Antineoplastic agents
- C12Q 2600/106: Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
- C12Q 2600/156: Polymorphic or mutational markers
- C12Q: MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS (immunoassay G01N33/53); COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present invention relates to a mutant of MITF which is useful as a marker for predisposition to the development of cancer and to uses thereof in diagnosis and preventive treatments, sumoylation being reduced or absent in this mutant.

## Claims

### Claim at position 1

1-13. (canceled)

### Claim 14

A method for determining whether a subject has a predisposition or a susceptibility to develop a cancer selected from the group consisting of a cutaneous malignant melanoma, a neuroendocrine cancer, a sarcoma, a neuroblastoma, a nervous system tumor (NST), a lymphoma, a lung cancer, a renal cancer, a breast cancer, a pancreatic cancer, a pediatric tumor, a hematopoietic malignancy, a gastrointestinal cancer, a polycythemia, and combinations thereof, comprising determining in a biological sample from the subject the presence of a mutation in microphthalmia-associated transcription factor (MITF), said mutation reducing or abolishing the sumoylation of MITF and the presence of said mutation indicating that the subject has a predisposition or a susceptibility to develop such cancer.

### Claim 15 (depends on 14)

The method according to claim 14, wherein the MITF mutation is a substitution of a lysine residue and/or a glutamic acid residue of one of the MITF sumoylation sites or of both sites.

### Claim 16 (depends on 15)

The method according to claim 15, wherein the mutation is the substitution of a residue selected from the table below by any of the other 19 amino acids.
1st
2nd
sumoylation
sumoylation
Isoform
SEQ ID No
Transcript ref.
Protein ref.
site
site
ISOFORM 1
35
NM_198159
NP_937802
K289
E291
K417
E419
ISOFORM 2
36
NM_198177
NP_937820
K273
E275
K401
E403
ISOFORM 3
37
NM_006722
NP_006713
K288
E290
K416
E418
ISOFORM 4
38
NM_000248
NP_000239
K182
E184
K316
E318
ISOFORM 5
39
NM_198158
NP_937801
K182
E184
K310
E312
SOFORM 6
40
NM_198178
NP_937821
K126
E128
K254
E256

### Claim 17 (depends on 16)

The method according to claim 16, wherein the mutation is a substitution of K316 or E318 of isoform 4 or of the corresponding residue in the other MITF isoforms.

### Claim 18 (depends on 17)

The method according to claim 17, wherein the mutation is a substitution of E318 of isoform 4 or of the corresponding residue in the other MITF isoforms.

### Claim 19 (depends on 18)

The method according to claim 18, wherein E318 is substituted with a lysine.

### Claim 20 (depends on 14)

The method according to claim 14, wherein the mutation is detected at the protein or nucleic level.

### Claim 21 (depends on 14)

The method according to claim 14, wherein the mutation is detected indirectly by measuring sumoylation of MITF, a reduction of sumoylation relative to the wild-type MITF protein indicating the presence of the E318K mutation.

### Claim 22 (depends on 21)

The method according to claim 21, wherein the mutation is detected by determining the cellular localization of MITF by immunohistochemistry, a nuclear localization being indicative of the wild-type MITF protein while a nuclear and cytoplasmic localization being indicative of the MITF E318K mutant protein.

### Claim 23 (depends on 14)

The method according to claim 14, wherein the cancer is selected from among the combination of a cutaneous malignant melanoma and a renal cell carcinoma, polycythemia, and lymphomas, preferably a cutaneous malignant melanoma and a kidney cancer.

### Claim 24 (depends on 14)

The method according to claim 14, said method further comprising the administration of an effective therapeutic dose of polyphenolic compounds to a subject having reduced or abolished sumoylation of MITF.

### Claim 25 (depends on 24)

The method according to claim 24, wherein the polyphenolic compounds are polyphenolic compounds from fermented rice hulls or polyphenols from black tea.

### Claim 26 (depends on 14)

A method for selecting patients who may benefit from a preventive treatment of cancer or a medical surveillance for early detection of cancer comprising determining the patient's susceptibility to cancer by the method according to claim 14 and selecting subjects carrying the mutation reducing or abolishing the sumoylation of MITF.

### Claim 27 (depends on 26)

The method according to claim 26, wherein it further comprises administering an effective therapeutic dose of polyphenolic compounds to selected subjects, thereby preventing or delaying the development of a cancer.

### Claim 28 (depends on 27)

The method according to claim 27, wherein the polyphenolic compounds arc polyphenolic compounds from fermented rice hulls or polyphenols from black tea.

### Claim 29

A method for delaying cancer in a subject carrying a mutation that reduces or abolishes the sumoylation of MITF, comprising administering an effective therapeutic dose of polyphenolic compounds to a subject having reduced or abolished sumoylation of MITF, said effective therapeutic dose delaying the development of a cancer.

### Claim 30 (depends on 29)

The method according to claim 29, wherein the polyphenolic compounds are polyphenolic compounds from fermented rice hulls or polyphenols from black tea.
